The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma
| Autor: | Subir Nag, D. Jeffrey Demanes, Elmer R. Cano, Ajmel A. Puthawala, Bhadrasain Vikram |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Brachytherapy MEDLINE medicine Humans Radiology Nuclear Medicine and imaging Medical physics Survival rate Intraoperative Care Radiation business.industry Dose fractionation Cancer Nasopharyngeal Neoplasms Radiotherapy Dosage Guideline medicine.disease High-Dose Rate Brachytherapy Surgery Survival Rate Radiation therapy Oropharyngeal Neoplasms Oncology Head and Neck Neoplasms Lymphatic Metastasis Mouth Neoplasms Radiotherapy Adjuvant Dose Fractionation Radiation Neoplasm Recurrence Local Safety business Paranasal Sinus Neoplasms |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 50:1190-1198 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/s0360-3016(01)01567-x |
| Popis: | Purpose: To develop recommendations for use of high-dose-rate (HDR) brachytherapy in patients with head-and-neck cancer. Methods: A panel consisting of members of the American Brachytherapy Society (ABS) performed a literature review, added information based upon their clinical experience, and formulated recommendations for head-and-neck HDR brachytherapy. Results: The ABS recommends the use of brachytherapy as a component of the treatment of head-and-neck tumors. However, the ABS recognizes that some radiation oncologists are reluctant to employ brachytherapy in the head-and-neck region because of the complexity of the postoperative management and concerns about radiation safety. In this regard, HDR eliminates unwanted radiation exposure and thereby permits unrestricted delivery of clinical care to these brachytherapy patients. The ABS made specific recommendations for previously untreated and recurrent head-and-neck cancer patients on patient selection criteria, implant techniques, target volume definition, and HDR treatment parameters (such as time, dose, and fractionation schedules). Suggestions were provided for treatment with HDR alone and in combination with external beam radiation therapy. It should be recognized that only limited experiences exist with HDR brachytherapy in patients with head-and-neck cancers. Therefore, some of these suggested doses have not been extensively tested in clinical practice. Hence, these guidelines will be updated as significant new outcome data are available. Any clinician following these guidelines is expected to use clinical judgment to determine an individual patient’s treatment. Conclusions: Little has been published in the clinical literature on HDR brachytherapy in head-and-neck cancer. Based upon the available information and the clinical experience of the panel members, general and site-specific recommendations were offered. Areas for further investigations were identified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|